Results 21 to 30 of about 66,330 (250)

RNA-induced epigenetic silencing inhibits HIV-1 reactivation from latency [PDF]

Retrovirology, 2018
Background Current antiretroviral therapy is effective in controlling HIV-1 infection. However, cessation of therapy is associated with rapid return of viremia from the viral reservoir.
Catalina Méndez, Scott Ledger, Kathy Petoumenos, Chantelle Ahlenstiel, Anthony D. Kelleher   +4 more
doaj   +3 more sources

A Canadian Survey of Research on HIV-1 Latency—Where Are We Now and Where Are We Heading? [PDF]

Viruses
Worldwide, almost 40 million people are currently living with HIV-1. The implementation of cART inhibits HIV-1 replication and reduces viremia but fails to eliminate HIV-1 from latently infected cells.
Ana Luiza Abdalla, Gabriel Guajardo-Contreras, Andrew J. Mouland   +2 more
doaj   +2 more sources

HIV-1 latency reversal agent boosting is not limited by opioid use [PDF]

JCI Insight
Opioid use may affect the HIV-1 reservoir and its reversal from latency. We studied 47 virally suppressed people with HIV (PWH) and observed that lower concentration of HIV-1 latency reversal agents (LRAs), used with small molecules that did not reverse ...
Tyler Lilie, Jennifer Bouzy, Archana Asundi, Jessica Taylor, Samantha Roche, Alex Olson, Kendyll Coxen, Heather Corry, Hannah Jordan, Kiera Clayton, Nina Lin, Athe Tsibris   +11 more
doaj   +2 more sources

THE ROLE OF VPR IN HIV-1 LATENCY [PDF]

Although antiretroviral therapy (ART) has dramatically improved the clinical prognosis for people with HIV and prevents transmission, ART is not a cure. This is because of a latent reservoir that persists in long-lived cells such as central memory CD4+ T (TCM) cells.
Lewis, Cat
openaire   +3 more sources

BRD9 functions as an HIV-1 latency regulatory factor. [PDF]

Proc Natl Acad Sci U S A
A major challenge for HIV type 1 (HIV-1) cure is the presence of viral latent reservoirs. The “Shock & Kill” strategy involves the combined use of latency reversal agents (LRA) and antiretroviral treatment (ART) to reactivate HIV-1 latent reservoirs ...
Luk TY, Yim LY, Zhou R, Mo Y, Huang H, Zhao M, Dai J, Lau TT, Huang X, Lui GC, Yuen KY, Chan JF, Cheng AS, Chen Z, Chu H.   +14 more
europepmc   +3 more sources

HIV-1 latency: From acquaintance to confidant. [PDF]

J Virus Erad
Antiretroviral therapy (ART) has transformed HIV from a fatal disease into manageable circumstance. However, the HIV reservoirs remain a main barrier to complete cure. This review emphasized when, where and how the latency is established, with focus on various host factors and viral proteins.
Yang C, Tong L, Xue J.
europepmc   +4 more sources

HIV-1: To Splice or Not to Splice, That Is the Question

Viruses, 2021
The transcription of the HIV-1 provirus results in only one type of transcript—full length genomic RNA. To make the mRNA transcripts for the accessory proteins Tat and Rev, the genomic RNA must completely splice.
Ann Emery, Ronald Swanstrom
doaj   +1 more source

Transcriptome profiles of latently- and reactivated HIV-1 infected primary CD4+ T cells: A pooled data-analysis

Frontiers in Immunology, 2022
The main obstacle to cure HIV-1 is the latent reservoir. Antiretroviral therapy effectively controls viral replication, however, it does not eradicate the latent reservoir. Latent CD4+ T cells are extremely rare in HIV-1 infected patients, making primary
Anne Inderbitzin, Anne Inderbitzin, Anne Inderbitzin, Tom Loosli, Tom Loosli, Tom Loosli, Lennart Opitz, Peter Rusert, Karin J. Metzner, Karin J. Metzner   +9 more
doaj   +1 more source

FKBP3 Induces Human Immunodeficiency Virus Type 1 Latency by Recruiting Histone Deacetylase 1/2 to the Viral Long Terminal Repeat

mBio, 2021
Human immunodeficiency virus type 1 (HIV-1) cannot be completely eliminated because of existence of the latent HIV-1 reservoir. However, the facts of HIV-1 latency, including its establishment and maintenance, are incomplete.
Xinyi Yang, Xiaying Zhao, Yuqi Zhu, Yinzhong Shen, Yanan Wang, Panpan Lu, Zhengtao Jiang, Hanyu Pan, Jinlong Yang, Jingna Xun, Lin Zhao, Jing Wang, Zhiming Liang, Xiaoting Shen, Yue Liang, Qinru Lin, Huitong Liang, Lu Jin, Dengji Zhang, Jun Liu, Bin Wang, Shibo Jiang, Jianqing Xu, Hao Wu, Hongzhou Lu, Huanzhang Zhu   +25 more
doaj   +1 more source

HIV-1 Latency by Transition [PDF]

Immunity, 2017
The latent HIV-1 reservoir represents the major barrier for the development of an HIV-1 cure. In this issue of Immunity, Shan et al. (2017) highlight that effector-to-memory transitioning (EMT) CD4+ T cells are particularly permissive for the establishment of latent HIV-1 infection.
Boris, Julg, Dan H, Barouch
openaire   +2 more sources